Enrollment failures in lupus nephritis trials rarely begin at the site. They begin in the protocol, when eligibility criteria are written around biomarker behavior that the disease does not actually exhibit. Flares are narrow and biologically variable, and the standard serological panel used across SLE studies is too noisy to reliably open an enrollment window for an individual patient. This article examines how urine biomarkers can serve as more precise eligibility signals, how patient-administered monitoring creates a faster referral path, and how sponsor teams can write protocols that align disease biology with practical execution at the patient, site, and operational levels.
Read the full article to learn about:
- Why standard serological markers (e.g., anti-dsDNA antibodies and complement levels C3 and C4) are imprecise as enrollment gates, and what emerging urinary biomarkers offer instead
- How urinary candidates such as CD163 and IP-10 (CXCL10) can extend the screening window by predicting flares weeks to months before clinical presentation
- The three protocol design choices most likely to determine enrollment success: selecting a predictive rather than confirmatory eligibility biomarker, confirming assay feasibility at selected sites, and building patient self-monitoring as a defined referral signal
